Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

被引：0

作者：

Sylvie Négrier

David Pérol

Rastislav Bahleda

Antoine Hollebecque

Etienne Chatelut

Helen Boyle

Philippe Cassier

Séverine Metzger

Ellen Blanc

Jean-Charles Soria

Bernard Escudier

机构：

[1] University Lyon,Department of Medical Oncology

[2] Université Claude Bernard Lyon 1,undefined

[3] Centre Léon Bérard,undefined

[4] Clinical Research and Innovation Department,undefined

[5] Centre Léon Bérard,undefined

[6] DITEP -Département d’Innovation Thérapeutiques et Essais Précoces,undefined

[7] Institut Gustave Roussy,undefined

[8] Institut Claudius Regaud,undefined

[9] Inserm UMR1037 CRCT,undefined

[10] Université Paul-Sabatier,undefined

[11] Medical Oncology Department,undefined

[12] Centre Léon Bérard,undefined

[13] University of Paris Sud,undefined

[14] Orsay,undefined

[15] Institut Gustave Roussy,undefined

[16] Institut Gustave Roussy,undefined

来源：

BMC Cancer | / 17卷

关键词：

Renal carcinoma; Bevacizumab; Pazopanib; Combination Angiogenesis; Phase I trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 258 条

[1] Yang JC(2003)A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427-434
[2] Haworth L(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342
[3] Sherry RM(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[4] Hwu P(2007)Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666-2676
[5] Schwartzentruber DJ(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[6] Topalian SL(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124
[7] Hurwitz H(2007)Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103-2111
[8] Fehrenbacher L(2010)Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 1061-1068
[9] Novotny W(2007)Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271-2281
[10] Cartwright T(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125-134